Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results

기사 요약

Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.